News
Attorneys
IPO Education Foundation Celebration 2024
IPO Education Foundation Celebration 2024
Cantor Colburn is proud to sponsor the 2024 IPO Education Foundation Awards Celebration which recognizes the Inventor of the Year, Executive of the Year, and the IP Champion. The event takes place on December 12, 2024 in Washington. D.C.
Cantor Colburn is a long time supporter of the IPO Education Foundation, a non-profit organization devoted to educational and charitable activities designed to promote the value of intellectual property rights. The firm is pleased to honor all of the 2023 Honorees, and notes the strong ties to Connecticut, our headquarters state, among this year's outstanding recipients:
The Inventor of the Year award recognizes the world’s most outstanding recent inventors and how they benefit the nation’s economy and quality of life. The 2024 award goes to the inventors of Mounjaro (Eli Lilly) and Ozempic (Novo Nordisk) for identifying novel compounds targeting incretin hormones to treat diabetes. The honorees from Eli Lilly include Bengt Krister Bokvist, Tamer Coskun, Robert Chadwick Cummins, and Jorge Alsina-Fernandez. The honorees from Novo Nordisk include Jesper Lau, Paw Bloch, and Thomas Kruse Hansen. These medications have made significant positive impacts on the lives of those affected by diabetes by lowering A1C and the risk of major cardiovascular events such as stroke, heart attack, or death in adults also with known heart disease.
The 2024 Executive of the Year award goes to Dr. Martine Rothblatt (United Therapeutics Corp.) for her commitment to the creation, promotion, and protection of intellectual property. Dr. Rothblatt, an inventor and entrepreneur, has made transformative contributions across various fields, including telecommunications with the creation of SiriusXM, biotechnology, and aviation. Dr. Rothblatt founded United Therapeutics in 1996 after her daughter was diagnosed with life threatening pulmonary hypertension. Under her leadership as Chairperson and CEO, the company developed a successful treatment for this condition, impacting and improving the lives of many patients. Beyond her work with United Therapeutics, Dr. Rothblatt has been a driving force in the biotech industry, advancing treatments and research that address significant medical challenges.
